Adeshwar Meditex Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1003503,
    "name": "Adeshwar Meditex",
    "stock_name": "Adeshwar Meditex",
    "full_name": "Adeshwar Meditex Ltd",
    "name_url": "stocks-analysis/adeshwar-meditex",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "16.50",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "16.50",
    "mcapval": "26.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 543309,
    "symbol": "",
    "ind_name": "Healthcare Services",
    "ind_code": 26,
    "indexname": "",
    "isin": "INE0H8J01015",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": 6000,
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/adeshwar-meditex-1003503-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Adeshwar Meditex overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-adeshwar-meditex-overvalued-or-undervalued-3700275",
        "imagepath": "",
        "date": "2025-11-14 08:12:08",
        "description": "As of 13 November 2025, Adeshwar Meditex has moved from a fair to an attractive valuation grade, indicating a more favorable outlook for the company. The stock is currently considered undervalued, especially when compared to its peers. Key ratios include a PE ratio of 11.33, an EV to EBITDA of 6.75, and a Price to Book Value of 0.62, which suggest that the company is trading at a significant discount relative to its earnings and asset value.\n\nIn comparison to its peers, Adeshwar Meditex stands out with a much lower PE ratio than Poly Medicure, which has a PE of 55.2, and Blue Jet Health at 28.63. The EV to EBITDA ratio of 6.75 also highlights its attractiveness compared to other expensive peers like Laxmi Dental at 38.93. Despite the recent underperformance of Adeshwar Meditex's stock against the Sensex, with a YTD return of -37.5% compared to the Sensex's 8.11%, the current valuation metrics suggest that i..."
      },
      {
        "title": "How has been the historical performance of Adeshwar Meditex?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-adeshwar-meditex-3695611",
        "imagepath": "",
        "date": "2025-11-13 00:32:27",
        "description": "Answer:\nThe historical performance of Adeshwar Meditex shows a consolidated net profit of 0.79 crore for the year ending March 2022, with net sales recorded at 64.76 crore. The total operating income for the same period was also 64.76 crore, while total expenditure, excluding depreciation, amounted to 61.39 crore, resulting in an operating profit (PBDIT) of 3.60 crore. The profit before tax was 1.19 crore, leading to a profit after tax of 0.79 crore. The earnings per share (EPS) stood at 0.55, with a diluted EPS of 0.59. The operating profit margin was 5.2%, and the profit after tax margin was 1.22%. \n\nIn terms of balance sheet performance, the total liabilities as of March 2022 were 72.45 crore, with total assets also at 72.45 crore. The company's shareholder's funds were reported at 30.95 crore. Over the years, the book value per share has shown a steady increase, reaching 21.45 by March 2022. Cash flow f..."
      },
      {
        "title": "When is the next results date for Adeshwar Meditex?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-adeshwar-meditex-3687248",
        "imagepath": "",
        "date": "2025-11-10 23:16:36",
        "description": "The next results date for Adeshwar Meditex is scheduled for 12 November 2025...."
      },
      {
        "title": "Is Adeshwar Meditex overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-adeshwar-meditex-overvalued-or-undervalued-3684220",
        "imagepath": "",
        "date": "2025-11-10 08:12:56",
        "description": "As of 7 November 2025, Adeshwar Meditex's valuation grade has moved from expensive to fair, indicating a more favorable assessment of its market position. The company is currently fairly valued, with a PE ratio of 12.77, an EV to EBITDA of 8.25, and a Price to Book Value of 0.71. These figures suggest that the company is trading at reasonable multiples compared to its earnings and asset values.\n\nIn comparison to its peers, Adeshwar Meditex stands out as more attractively priced than companies like Poly Medicure, which has a PE ratio of 53.67, and Vimta Labs, with a PE ratio of 47.83. While Adeshwar Meditex has faced challenges in stock performance, particularly with a year-to-date return of -26.04% compared to the Sensex's 6.50%, its current valuation metrics indicate that it is not overvalued, especially in a sector where many peers are significantly more expensive...."
      },
      {
        "title": "Is Adeshwar Meditex overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-adeshwar-meditex-overvalued-or-undervalued-3682897",
        "imagepath": "",
        "date": "2025-11-09 08:11:12",
        "description": "As of 7 November 2025, Adeshwar Meditex has moved from an expensive to a fair valuation grade. The company's current valuation indicates it is fairly valued. Key ratios include a PE ratio of 12.77, an EV to EBITDA of 8.25, and a Price to Book Value of 0.71, which suggest a reasonable pricing relative to its earnings and assets.\n\nIn comparison to its peers, Adeshwar Meditex's PE ratio is significantly lower than that of Poly Medicure, which stands at 53.67, and Blue Jet Health at 29.26, both categorized as very expensive. The company's EV to EBITDA ratio of 8.25 also positions it more favorably compared to peers like Vimta Labs, which has an EV to EBITDA of 25.64. Notably, while Adeshwar Meditex has underperformed the Sensex over the longer term, it has shown a positive return of 3.95% over the past week, contrasting with the Sensex's decline...."
      },
      {
        "title": "Is Adeshwar Meditex overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-adeshwar-meditex-overvalued-or-undervalued-3681923",
        "imagepath": "",
        "date": "2025-11-08 08:11:03",
        "description": "As of 7 November 2025, Adeshwar Meditex has moved from an expensive to a fair valuation grade. The company is currently fairly valued, with a PE ratio of 12.77, an EV to EBITDA of 8.25, and an EV to Sales ratio of 0.43. In comparison to its peers, Poly Medicure is very expensive with a PE ratio of 53.67, while BPL stands out as very attractive with a PE ratio of 6.38.\n\nDespite the recent fair valuation, Adeshwar Meditex has underperformed relative to the Sensex, particularly over the year with a stock return of -18.38% compared to the Sensex's 4.62%. This discrepancy highlights the potential for future growth as the company aligns its performance with market expectations...."
      },
      {
        "title": "Is Adeshwar Meditex overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-adeshwar-meditex-overvalued-or-undervalued-3678080",
        "imagepath": "",
        "date": "2025-11-07 08:12:22",
        "description": "As of 6 November 2025, Adeshwar Meditex's valuation grade has moved from fair to expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 13.41, an EV to EBITDA of 8.56, and a PEG ratio of 4.49, which indicates that the stock may not justify its current price based on its earnings growth potential.\n\nIn comparison to its peers, Adeshwar Meditex's PE ratio is significantly lower than that of Poly Medicure, which has a PE of 53.88, and Blue Jet Health, with a PE of 27.66, both categorized as very expensive. The company's recent stock performance has been underwhelming, with a year-to-date return of -26.04%, contrasting sharply with the Sensex's gain of 6.62% during the same period, reinforcing the notion that the stock is overvalued...."
      },
      {
        "title": "Is Adeshwar Meditex overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-adeshwar-meditex-overvalued-or-undervalued-3660291",
        "imagepath": "",
        "date": "2025-10-31 08:10:26",
        "description": "As of 30 October 2025, Adeshwar Meditex's valuation grade has moved from expensive to fair, indicating a shift in its market perception. The company is currently fairly valued. Key ratios include a PE ratio of 12.90, an EV to EBITDA of 8.32, and a Price to Book Value of 0.72, which suggest that the company is positioned reasonably within the market.\n\nIn comparison to its peers, Adeshwar Meditex's PE ratio of 12.90 is significantly lower than that of Poly Medicure at 55.91 and Blue Jet Health at 31.35, both categorized as very expensive. This indicates that Adeshwar Meditex may offer a more attractive valuation relative to these peers. Despite a recent decline in stock price, the company's performance over the past month has outpaced the Sensex, returning 7.25% compared to the Sensex's 5.15%...."
      },
      {
        "title": "Is Adeshwar Meditex overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-adeshwar-meditex-overvalued-or-undervalued-3657189",
        "imagepath": "",
        "date": "2025-10-30 08:08:36",
        "description": "As of 29 October 2025, Adeshwar Meditex's valuation grade has moved from fair to expensive, indicating a shift in its perceived value. The company is currently overvalued, with a PE ratio of 14.15, an EV to EBITDA ratio of 8.91, and a PEG ratio of 4.74. These figures suggest that the stock may not justify its current price given its earnings growth prospects.\n\nIn comparison to its peers, Adeshwar Meditex's PE ratio is significantly lower than that of Poly Medicure, which stands at 55.86, and Vimta Labs, which has a PE of 49.13. This indicates that while Adeshwar Meditex is considered expensive, it is still more attractively priced than some of its peers. Additionally, the stock has underperformed against the Sensex, particularly in the year-to-date period, where it has returned -21.92% compared to the Sensex's 8.78%...."
      }
    ],
    "total": 34,
    "sid": "1003503",
    "stock_news_url": "https://www.marketsmojo.com/news/adeshwar-meditex-1003503"
  },
  "announcements": [
    {
      "caption": "Unaudited Financial Results For The Half Year Ended September 30 2025",
      "datetime": "12-Nov-2025",
      "details": "Unaudited Financial Results for the half year ended September 302025",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E On Wednesday November 12 2025",
      "datetime": "12-Nov-2025",
      "details": "Outcome of Board Meeting held today i.e on Wednesday November 12 2025",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Board Meeting Of The Company To Be Held On November 12 2025 Through Video Conferencing At 12.00 Noon (IST)",
      "datetime": "07-Nov-2025",
      "details": "Adeshwar Meditex Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 inter alia to consider and approve Adeshwar Meditex Limited has informed BSE that the meeting of the Board of Directors of the Company is scheduled on November 12 2025 through Video Conferencing at 12.00 NOON (IST) inter alia to consider and approve: To take note of demise of Mr. Benegal Parameshwara Udpa (DIN: 08563819) Non-Executive Independent Director of the Company; To consider and approve the Standalone Un-Audited Financial Result of the Company along with Limited Review Report (LRR) for the half year ended September 30 2025; To consider and approve the changes in signatories of all the banks of the Company; Any other matter with the permission of the Chair",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Adeshwar Meditex overvalued or undervalued?

2025-11-14 08:12:08

As of 13 November 2025, Adeshwar Meditex has moved from a fair to an attractive valuation grade, indicating a more favorable outlook for the company. The stock is currently considered undervalued, especially when compared to its peers. Key ratios include a PE ratio of 11.33, an EV to EBITDA of 6.75, and a Price to Book Value of 0.62, which suggest that the company is trading at a significant discount relative to its earnings and asset value. In comparison to its peers, Adeshwar Meditex stands out with a much lower PE ratio than Poly Medicure, which has a PE of 55.2, and Blue Jet Health at 28.63. The EV to EBITDA ratio of 6.75 also highlights its attractiveness compared to other expensive peers like Laxmi Dental at 38.93. Despite the recent underperformance of Adeshwar Meditex's stock against the Sensex, with a YTD return of -37.5% compared to the Sensex's 8.11%, the current valuation metrics suggest that i...

How has been the historical performance of Adeshwar Meditex?

2025-11-13 00:32:27

Answer: The historical performance of Adeshwar Meditex shows a consolidated net profit of 0.79 crore for the year ending March 2022, with net sales recorded at 64.76 crore. The total operating income for the same period was also 64.76 crore, while total expenditure, excluding depreciation, amounted to 61.39 crore, resulting in an operating profit (PBDIT) of 3.60 crore. The profit before tax was 1.19 crore, leading to a profit after tax of 0.79 crore. The earnings per share (EPS) stood at 0.55, with a diluted EPS of 0.59. The operating profit margin was 5.2%, and the profit after tax margin was 1.22%. In terms of balance sheet performance, the total liabilities as of March 2022 were 72.45 crore, with total assets also at 72.45 crore. The company's shareholder's funds were reported at 30.95 crore. Over the years, the book value per share has shown a steady increase, reaching 21.45 by March 2022. Cash flow f...

When is the next results date for Adeshwar Meditex?

2025-11-10 23:16:36

The next results date for Adeshwar Meditex is scheduled for 12 November 2025....

Is Adeshwar Meditex overvalued or undervalued?

2025-11-10 08:12:56

As of 7 November 2025, Adeshwar Meditex's valuation grade has moved from expensive to fair, indicating a more favorable assessment of its market position. The company is currently fairly valued, with a PE ratio of 12.77, an EV to EBITDA of 8.25, and a Price to Book Value of 0.71. These figures suggest that the company is trading at reasonable multiples compared to its earnings and asset values. In comparison to its peers, Adeshwar Meditex stands out as more attractively priced than companies like Poly Medicure, which has a PE ratio of 53.67, and Vimta Labs, with a PE ratio of 47.83. While Adeshwar Meditex has faced challenges in stock performance, particularly with a year-to-date return of -26.04% compared to the Sensex's 6.50%, its current valuation metrics indicate that it is not overvalued, especially in a sector where many peers are significantly more expensive....

Is Adeshwar Meditex overvalued or undervalued?

2025-11-09 08:11:12

As of 7 November 2025, Adeshwar Meditex has moved from an expensive to a fair valuation grade. The company's current valuation indicates it is fairly valued. Key ratios include a PE ratio of 12.77, an EV to EBITDA of 8.25, and a Price to Book Value of 0.71, which suggest a reasonable pricing relative to its earnings and assets. In comparison to its peers, Adeshwar Meditex's PE ratio is significantly lower than that of Poly Medicure, which stands at 53.67, and Blue Jet Health at 29.26, both categorized as very expensive. The company's EV to EBITDA ratio of 8.25 also positions it more favorably compared to peers like Vimta Labs, which has an EV to EBITDA of 25.64. Notably, while Adeshwar Meditex has underperformed the Sensex over the longer term, it has shown a positive return of 3.95% over the past week, contrasting with the Sensex's decline....

Is Adeshwar Meditex overvalued or undervalued?

2025-11-08 08:11:03

As of 7 November 2025, Adeshwar Meditex has moved from an expensive to a fair valuation grade. The company is currently fairly valued, with a PE ratio of 12.77, an EV to EBITDA of 8.25, and an EV to Sales ratio of 0.43. In comparison to its peers, Poly Medicure is very expensive with a PE ratio of 53.67, while BPL stands out as very attractive with a PE ratio of 6.38. Despite the recent fair valuation, Adeshwar Meditex has underperformed relative to the Sensex, particularly over the year with a stock return of -18.38% compared to the Sensex's 4.62%. This discrepancy highlights the potential for future growth as the company aligns its performance with market expectations....

Is Adeshwar Meditex overvalued or undervalued?

2025-11-07 08:12:22

As of 6 November 2025, Adeshwar Meditex's valuation grade has moved from fair to expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 13.41, an EV to EBITDA of 8.56, and a PEG ratio of 4.49, which indicates that the stock may not justify its current price based on its earnings growth potential. In comparison to its peers, Adeshwar Meditex's PE ratio is significantly lower than that of Poly Medicure, which has a PE of 53.88, and Blue Jet Health, with a PE of 27.66, both categorized as very expensive. The company's recent stock performance has been underwhelming, with a year-to-date return of -26.04%, contrasting sharply with the Sensex's gain of 6.62% during the same period, reinforcing the notion that the stock is overvalued....

Is Adeshwar Meditex overvalued or undervalued?

2025-10-31 08:10:26

As of 30 October 2025, Adeshwar Meditex's valuation grade has moved from expensive to fair, indicating a shift in its market perception. The company is currently fairly valued. Key ratios include a PE ratio of 12.90, an EV to EBITDA of 8.32, and a Price to Book Value of 0.72, which suggest that the company is positioned reasonably within the market. In comparison to its peers, Adeshwar Meditex's PE ratio of 12.90 is significantly lower than that of Poly Medicure at 55.91 and Blue Jet Health at 31.35, both categorized as very expensive. This indicates that Adeshwar Meditex may offer a more attractive valuation relative to these peers. Despite a recent decline in stock price, the company's performance over the past month has outpaced the Sensex, returning 7.25% compared to the Sensex's 5.15%....

Is Adeshwar Meditex overvalued or undervalued?

2025-10-30 08:08:36

As of 29 October 2025, Adeshwar Meditex's valuation grade has moved from fair to expensive, indicating a shift in its perceived value. The company is currently overvalued, with a PE ratio of 14.15, an EV to EBITDA ratio of 8.91, and a PEG ratio of 4.74. These figures suggest that the stock may not justify its current price given its earnings growth prospects. In comparison to its peers, Adeshwar Meditex's PE ratio is significantly lower than that of Poly Medicure, which stands at 55.86, and Vimta Labs, which has a PE of 49.13. This indicates that while Adeshwar Meditex is considered expensive, it is still more attractively priced than some of its peers. Additionally, the stock has underperformed against the Sensex, particularly in the year-to-date period, where it has returned -21.92% compared to the Sensex's 8.78%....

View All News